ENERGY AMPLIFYING NANOGELS
Theromics is developing a next-generation thermal accelerant technology for enhanced ablation procedures and more precise and effective drug delivery.
How it Works ApplicationsTechnology: How It Works
Theromics has developed a nanopolymer platform technology to address the shortcomings of thermal ablation of soft tissue. HeatSYNC™ and CryoSYNC gels are IP-protected, biocompatible and made of human proteins that facilitate energy transfer in human tissue allowing for larger and more effective soft tissue ablations to mitigate the current 30% recurrence rate. In addition, the gel can be delivered directly into a tumor and combine ablation and therapeutics to localize the therapy in a controlled fashion and mitigate the systemic side effects of these therapies. We call this new therapy “TACT – Thermally Activated Combination Therapy.”
Ablation Benefits
mitigates “heat sinks”
Absorbs energy effectively preventing heat loss caused by blood flow in large vessels adjacent to ablation zone
Improves Thermal penetration
Optimizes the shape of the ablation zone into a sphere making the ablation volume predictable
Accurate targeting
Produces a larger ablation area making it easier to target the tumor center and optimizes antenna guidance into tumor mass
applications
Theromics’ temperature-controlled nanogel accelerants are being developed to provide more precise, enhanced treatment options for the following applications:
Current research indicates that up to 30 percent of soft tissue ablation treatments experience a recurrence that requires re-treatment. Inaccurate targeting, “heat-sinks,” and non-spherical ablation zones can all affect procedural success.
Theromics has developed an injectable platform nanopolymer to address these shortcomings and potentially reduce the recurrence associated with soft tissue ablation.
HeatSYNC™ and CryoSYNC gels are protected by intellectual property, biocompatible, and made of human proteins that facilitate energy transfer in human tissue, allowing for more extensive and effective soft tissue ablations. The gels can be used with all current ablation modalities, including RF, microwave, IRE, Cryoablation, and pulsed electric field (PEF), and can be delivered percutaneously, laparoscopically, or endobronchially. Testing has shown that a simple gel injection into the ablation site followed by treatment produces 50% larger and more spherical ablation zones in half the time.
Medicine is rapidly advancing towards utilizing minimally invasive combination treatments that offer enhanced efficacy while minimizing harm to the patient. This shift marks a departure from the days of simple resection or standalone drug courses. The groundbreaking Theromics nanogel exhibits the remarkable capability of synergizing with traditional small-molecule chemo drugs or cutting-edge immunotherapies.
This innovative nanogel can be delivered directly into diseased tissue and combined with ablation, ensuring seamless compatibility with existing treatments. The precision of this targeted delivery system enables the therapy to be administered in a controlled manner, effectively reducing the toxic, systemic side effects associated with traditional drug treatments. This pioneering approach, known as “TACT—Thermally Activated Combination Therapy,” represents a significant leap forward in the realm of medical treatment.
There are 600,000 hysterectomies performed every year in the US, and over half are due to uterine fibroids. Theromics’ HeatSYNC™ gel may offer an effective, minimally invasive alternative that preserves the uterus, is cost-effective, and presents fewer clinical challenges.
HeatSYNC™ gel is compatible with various energy sources, and the nanopolymer gel acts as an accelerator for any energy applied to the tissue. It is protein-based and biocompatible, facilitating energy movement in tissue due to its high polarity. This gel can enhance soft tissue ablation in uterine fibroids when combined with current existing ablation technologies. We envision further simplifying the procedure through a transvaginal approach, combining the gel with any “off-the-shelf” energy applicator. We also anticipate additional uses in abdominal wall endometriosis and breast cancer cryoablation.
Our Company
About Theromics
Theromics is leveraging next generation thermal accelerant technology to enhance soft tissue ablation procedures and more effectively deliver existing immunotherapy treatments. The company’s proprietary nanogels, HeatSYNC™ and CryoSYNC, are protein-based injectable nano-polymers that enhance the movement of energy in tissue, allowing more focused, precise ablations. Theromics was founded and spun out of Brown University in 2016 and is led by a team of accomplished clinicians, researchers and entrepreneurs committed to optimizing treatment strategies for a broad range of indications.
News & Press
MassVentures Announces $3 Million in Grant Funding for 17 Deep Tech Startups
MassVentures’ START program awarded Theromics Inc. funding to advance innovative technologies, including their injectable nanogel for cancer ablation and drug delivery. Theromics, alongside other awardees, are pioneering solutions to critical challenges, supporting Massachusetts’ economic growth, and transforming health, energy, and environmental industries.
